Notably, a metal-organic frameworks-based nanoagonist, DZ@A7, is engineered for tumor-specific, NIR light-enhanced delivery, activating the cGAS-STING pathway with minimized off-target effects. This evidence concerns the gene STING1 and neoplasm.